A freeze placed this year on their use to treat gender dysphoria will remain in place for young people under 18, except in ...

Creating contingency plans against geopolitical uncertainty was a key theme at the 2024 Outsourcing in Clinical Trials and ...

Organizations today are driven by the convergence of data, technology, and a new sense of urgency to recruit and retain ...

The companies plan to integrate and pilot their combined technologies to gain insight into improving cardiovascular care.

The decision, which will be revisited in 2027, effectively bans a common approach to medical gender transitions for youths.

The decision comes as the Supreme Court hears oral arguments for U.S v. Jonathan Skrmetti, a case which will determine the ...

Ban does not apply to those already receiving drugs for gender dysphoria, treatment of children with rarely diagnosed ...

The disease course in HAE can often fluctuate, necessitating close clinical observation and treatment adjustments when indicated.

Chimerix’s dordaviprone shows potential for glioma treatment with a possible FDA approval by 2025. Read why CMRX stock is a ...

Health Secretary Wes Streeting announced an indefinite ban on puberty blockers for under-18s with gender dysphoria (Ben ...

Anytime a new technological advancement makes its way into an industry, there can be a temptation to anoint that shiny new ...